

**Anti-CCR2 / CD192 Reference Antibody (plozalizumab)
Recombinant Antibody
Catalog # APR10318****Specification**

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P41597
Reactivity	Rat, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146.08 KDa

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Additional Information**Target/Specificity**
CCR2 / CD192**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Protein Information****Name** CCR2**Synonyms** CMKBR2**Function**
Key functional receptor for CCL2 but can also bind CCL7, and CCL12 (PubMed:23408426, PubMed:38157855, PubMed:8048929, PubMed:8146186). Also transduces signaling mediated by CCL13 (PubMed:38157855). Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (PubMed:38157855). Also acts as

a receptor for the beta-defensin DEFB106A/DEFB106B (PubMed:23938203). Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation (By similarity). Facilitates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R (By similarity). Plays an important role in mediating peripheral nerve injury-induced neuropathic pain (By similarity). Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B (By similarity). Mediates the recruitment of macrophages and monocytes to the injury site following brain injury (By similarity).

Cellular Location

Cell membrane; Multi-pass membrane protein. Note=The chemoattractant receptors are distributed throughout the cell surface; after stimulation with a ligand, such as CCL2, they are rapidly recruited into microdomain clusters at the cell membrane.

Tissue Location


Expressed by monocytes and IL2-activated NK cells (PubMed:9058802). Abundantly expressed on CD14+/CD16- monocytes and weakly on CD14+/CD16+ monocytes, type 2 dendritic cells (DCs) and plasmacytoid DCs (at protein level) (PubMed:38157855)

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Images



Anti-CCR2 / CD192 Reference Antibody (plozalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CCR2 / CD192 Reference Antibody (plozalizumab) is more than 99.45%, determined by SEC-HPLC.